Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Breast Cancer

Free Subscription Articles published in JAMA Retrieve available abstracts of 42 articles: HTML format

Single Articles

April 2025
1. FAN L, Shao ZM
   Camrelizumab vs Placebo in Patients With Triple-Negative Breast Cancer.
   JAMA. 2025 Apr 23. doi: 10.1001/jama.2025.1294.
   PubMed    
   
   
   
2. PEI YY
   Camrelizumab vs Placebo in Patients With Triple-Negative Breast Cancer.
   JAMA. 2025 Apr 23. doi: 10.1001/jama.2025.1291.
   PubMed    
   
   
   March 2025
3. HWANG ES, Hyslop T, Lynch T, Ryser MD, et al
   Active Monitoring With or Without Endocrine Therapy for Low-Risk Ductal Carcinoma In Situ: The COMET Randomized Clinical Trial.
   JAMA. 2025;333:972-980.
   PubMed     Abstract available
   
   
   
4. ANDERER S
   Trial: Less Frequent Mammograms Pose No Greater Risk After Breast Cancer.
   JAMA. 2025 Mar 7. doi: 10.1001/jama.2025.1346.
   PubMed    
   
   
   
5. LIM WH
   Breast Cancer and Levonorgestrel-Releasing Intrauterine Systems.
   JAMA. 2025 Mar 3. doi: 10.1001/jama.2024.27807.
   PubMed    
   
   
   
6. WESTHOFF CL, Pike MC, Pearce CL
   Breast Cancer and Levonorgestrel-Releasing Intrauterine Systems.
   JAMA. 2025 Mar 3. doi: 10.1001/jama.2024.27795.
   PubMed    
   
   
   
7. LUO P, Lin A, Miao K
   Breast Cancer and Levonorgestrel-Releasing Intrauterine Systems.
   JAMA. 2025 Mar 3. doi: 10.1001/jama.2024.27804.
   PubMed    
   
   
   
8. SLOTH MMB, Jorgensen TSH, Nybo Andersen AM
   Breast Cancer and Levonorgestrel-Releasing Intrauterine Systems.
   JAMA. 2025 Mar 3. doi: 10.1001/jama.2024.27798.
   PubMed    
   
   
   
9. LIBERTY AL, Rodriguez MI, Edelman A
   Breast Cancer and Levonorgestrel-Releasing Intrauterine Systems.
   JAMA. 2025 Mar 3. doi: 10.1001/jama.2024.27810.
   PubMed    
   
   
   
10. MORCH LS, Meaidi A, Corn G
    Breast Cancer and Levonorgestrel-Releasing Intrauterine Systems-Reply.
    JAMA. 2025 Mar 3. doi: 10.1001/jama.2024.27801.
    PubMed    
    
    
    January 2025
11. HUNTER N, Hurvitz S
    Where Did the Passion Go?-Rethinking Adjuvant Immune Therapy for Triple-Negative Breast Cancer.
    JAMA. 2025 Jan 30. doi: 10.1001/jama.2024.26811.
    PubMed    
    
    
    
12. IGNATIADIS M, Bailey A, McArthur H, El-Abed S, et al
    Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer: The ALEXANDRA/IMpassion030 Randomized Clinical Trial.
    JAMA. 2025 Jan 30. doi: 10.1001/jama.2024.26886.
    PubMed     Abstract available
    
    
    December 2024
13. JOENSUU H
    Neoadjuvant Camrelizumab for Triple-Negative Breast Cancer.
    JAMA. 2024 Dec 13. doi: 10.1001/jama.2024.25927.
    PubMed    
    
    
    
14. CHEN L, Li H, Zhang H, Yang H, et al
    Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer: The CamRelief Randomized Clinical Trial.
    JAMA. 2024 Dec 13. doi: 10.1001/jama.2024.23560.
    PubMed     Abstract available
    
    
    November 2024
15. ANDERER S
    ACOG Now Recommends Breast Cancer Screenings Start at Age 40.
    JAMA. 2024 Nov 15. doi: 10.1001/jama.2024.23048.
    PubMed    
    
    
    
16. ANDERER S
    Study: BMI May Underestimate Obesity-Linked Breast Cancer Risk.
    JAMA. 2024 Nov 15. doi: 10.1001/jama.2024.23049.
    PubMed    
    
    
    
17. ORRALL A
    Breast Cancer Incidence Still Rising Despite Decline in Death Rates.
    JAMA. 2024 Nov 1. doi: 10.1001/jama.2024.22056.
    PubMed    
    
    
    October 2024
18. MORCH LS, Meaidi A, Corn G, Hargreave M, et al
    Breast Cancer in Users of Levonorgestrel-Releasing Intrauterine Systems.
    JAMA. 2024 Oct 16. doi: 10.1001/jama.2024.18575.
    PubMed    
    
    
    September 2024
19. THORAT MA, Cuzick J, Chan AT
    Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer.
    JAMA. 2024 Sep 5. doi: 10.1001/jama.2024.15497.
    PubMed    
    
    
    
20. PETRELLI F, Ghidini A
    Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer.
    JAMA. 2024 Sep 5. doi: 10.1001/jama.2024.15491.
    PubMed    
    
    
    
21. LI C, He J, Liang W
    Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer.
    JAMA. 2024 Sep 5. doi: 10.1001/jama.2024.15488.
    PubMed    
    
    
    
22. SUN R, Wei LJ
    Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer.
    JAMA. 2024 Sep 5. doi: 10.1001/jama.2024.15494.
    PubMed    
    
    
    
23. CHEN WY, Ballman KV, Holmes MD
    Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer-Reply.
    JAMA. 2024 Sep 5. doi: 10.1001/jama.2024.15500.
    PubMed    
    
    
    
24. RYAN CE, Fasaye GA, Gallanis AF, Gamble LA, et al
    Germline CDH1 Variants and Lifetime Cancer Risk.
    JAMA. 2024;332:722-729.
    PubMed     Abstract available
    
    
    August 2024
25. HARRIS E
    More Data About Risks, Benefits Might Change Breast Cancer Screening Choice.
    JAMA. 2024 Aug 2. doi: 10.1001/jama.2024.13777.
    PubMed    
    
    
    July 2024
26. LEON-FERRE RA, Salgado R, Jonas SF
    Prognostic Value of Tumor-Infiltrating Lymphocytes for Patients With Triple-Negative Breast Cancer-Reply.
    JAMA. 2024 Jul 3. doi: 10.1001/jama.2024.10483.
    PubMed    
    
    
    
27. TU H, Zhang Y, You Z
    Prognostic Value of Tumor-Infiltrating Lymphocytes for Patients With Triple-Negative Breast Cancer.
    JAMA. 2024 Jul 3. doi: 10.1001/jama.2024.10480.
    PubMed    
    
    
    June 2024
28. RUBIN R
    Despite New Recommendations, the Debate Over Mammography Guidelines Continues.
    JAMA. 2024;331:1877-1879.
    PubMed    
    
    
    May 2024
29. MANSON JE, Crandall CJ, Rossouw JE, Chlebowski RT, et al
    The Women's Health Initiative Randomized Trials and Clinical Practice: A Review.
    JAMA. 2024;331:1748-1760.
    PubMed     Abstract available
    
    
    
30. MANDELBLATT JS, Mainor C, Hudson BI
    The Aspirin Conundrum-Navigating Negative Results, Age, Aging Dynamics, and Equity.
    JAMA. 2024;331:1709-1711.
    PubMed    
    
    
    
31. HARRIS E
    Young Patients Without Genetic Risk Have Low Chance of Second Breast Cancer.
    JAMA. 2024 May 3. doi: 10.1001/jama.2024.6734.
    PubMed    
    
    
    April 2024
32. TRENTHAM-DIETZ A, Chapman CH, Jayasekera J, Lowry KP, et al
    Collaborative Modeling to Compare Different Breast Cancer Screening Strategies: A Decision Analysis for the US Preventive Services Task Force.
    JAMA. 2024 Apr 30. doi: 10.1001/jama.2023.24766.
    PubMed     Abstract available
    
    
    
33. NICHOLSON WK, Silverstein M, Wong JB, Barry MJ, et al
    Screening for Breast Cancer: US Preventive Services Task Force Recommendation Statement.
    JAMA. 2024 Apr 30. doi: 10.1001/jama.2024.5534.
    PubMed     Abstract available
    
    
    
34. HENDERSON JT, Webber EM, Weyrich MS, Miller M, et al
    Screening for Breast Cancer: Evidence Report and Systematic Review for the US Preventive Services Task Force.
    JAMA. 2024 Apr 30. doi: 10.1001/jama.2023.25844.
    PubMed     Abstract available
    
    
    
35. 
    Screening for Breast Cancer.
    JAMA. 2024 Apr 30. doi: 10.1001/jama.2024.5535.
    PubMed    
    
    
    
36. ELMORE JG, Lee CI
    Toward More Equitable Breast Cancer Outcomes.
    JAMA. 2024 Apr 30. doi: 10.1001/jama.2024.6052.
    PubMed    
    
    
    
37. CHEN WY, Ballman KV, Partridge AH, Hahn OM, et al
    Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer: The Alliance A011502 Randomized Trial.
    JAMA. 2024 Apr 29:e244840. doi: 10.1001/jama.2024.4840.
    PubMed     Abstract available
    
    
    
38. CASWELL-JIN JL, Kurian AW, Plevritis SK
    US Breast Cancer Mortality-Reply.
    JAMA. 2024 Apr 25. doi: 10.1001/jama.2024.5482.
    PubMed    
    
    
    
39. JATOI I
    US Breast Cancer Mortality.
    JAMA. 2024 Apr 25. doi: 10.1001/jama.2024.5479.
    PubMed    
    
    
    
40. NAROD SA
    Breast Cancer and Pregnancy in Young BRCA Carriers.
    JAMA. 2024;331:1233-1234.
    PubMed    
    
    
    
41. BLONDEAUX E, Partridge AH, Lambertini M
    Breast Cancer and Pregnancy in Young BRCA Carriers-Reply.
    JAMA. 2024;331:1234.
    PubMed    
    
    
    
42. LEON-FERRE RA, Jonas SF, Salgado R, Loi S, et al
    Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer.
    JAMA. 2024;331:1135-1144.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.